This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

SQNM, NVS And ALXN, 3 Health Care Stocks Pushing The Sector Lower

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

One out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 3 points (0.0%) at 15,545 as of Thursday, July 25, 2013, 12:49 PM ET. The NYSE advances/declines ratio sits at 1,346 issues advancing vs. 1,602 declining with 83 unchanged.

The Health Care sector currently sits up 0.5% versus the S&P 500, which is unchanged. On the negative front, top decliners within the sector include Humana ( HUM), down 2.3%, Intuitive Surgical ( ISRG), down 2.5%, WellPoint ( WLP), down 1.7%, Bristol-Myers Squibb Company ( BMY), down 1.1% and Baxter International ( BAX), down 1.1%. Top gainers within the sector include Boston Scientific ( BSX), up 11.6%, Vertex Pharmaceuticals ( VRTX), up 2.5%, Amgen ( AMGN), up 1.9%, Celgene Corporation ( CELG), up 1.7% and Biogen Idec ( BIIB), up 1.4%.

TheStreet would like to highlight 3 stocks pushing the sector lower today:

3. Sequenom ( SQNM) is one of the companies pushing the Health Care sector lower today. As of noon trading, Sequenom is down $1.41 (-30.1%) to $3.28 on heavy volume. Thus far, 27.5 million shares of Sequenom exchanged hands as compared to its average daily volume of 2.4 million shares. The stock has ranged in price between $3.00-$3.42 after having opened the day at $3.07 as compared to the previous trading day's close of $4.69.

Sequenom, Inc., a life sciences company, provides genetic analysis solutions in the United States and internationally. It operates through two segments, Molecular Diagnostics and Genetic Analysis. Sequenom has a market cap of $519.3 million and is part of the drugs industry. Shares are down 4.2% year to date as of the close of trading on Wednesday. Currently there are 8 analysts that rate Sequenom a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Sequenom as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, generally high debt management risk and feeble growth in its earnings per share. Get the full Sequenom Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community

Markets

DOW 18,010.68 -115.44 -0.64%
S&P 500 2,107.39 -13.40 -0.63%
NASDAQ 5,070.0260 -27.95 -0.55%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs